Bruce Power Agrees to Produce Lutetium-177

​

Bruce Power and a subsidiary of Germany company ITM (Isotopen Technologien München), have agreed to explore the production of another medical radioisotope.

ITM is a specialized radiopharmaceutical company, and its subsidiary is ITG.

Lutetium-177 is used in Targeted Radionuclide Therapy to treat cancers like neuroendocrine tumours and prostate cancer.

Medical-grade Lutetium is used to destroy cancer cells while leaving healthy cells unaffected.  

The companies have signed a Memorandum of Understanding to explore the production of Lutetium-177 at the Bruce Power site, which has the ability to meet global supply needs through 2064.

The joint effort will explore how Lutetium-177 can be produced at Bruce Power's CANDU reactors.

To read more please visit:

http://www.bayshorebroadcasting.ca/news_item.php?NewsID=102598

Source: Bayshore Broadcasting Corporation